James Magee, MD
Endocrinology, Diabetes & Metabolism · Jacksonville, FLNPI 1801890389
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 447 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations.
Across 447 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Novo Nordisk$881
- Medtronic$650
- Insulet Corporation$647
- Amgen$563
- Lilly USA, LLC$416
- plus $3K from 30 others
Across 176 payments — averaging $15,609 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.3M
- Novartis$395K
- AbbVie$384K
- Sanofi US Services Inc.$256K
- Boehringer Ingelheim International GmbH$207K
- Boehringer Ingelheim Pharma GmbH & Co.kg$183K
- plus $70K from 3 others
What the payments were for
- Speaking & faculty fees$2503%
- Food & beverage$7,43897%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 88 | $1,660 |
| Novo Nordisk | 87 | $881 |
| Medtronic(2 entities) | 38 | $650 |
| Insulet Corporation | 39 | $647 |
| Amgen(2 entities) | 28 | $563 |
| Lilly USA, LLC | 22 | $416 |
| Bayer | 17 | $349 |
| Tandem Diabetes Care, Inc. | 7 | $338 |
| Sanofi-aventis U.S. LLC | 15 | $275 |
| Corcept Therapeutics | 13 | $266 |
| Xeris Pharmaceuticals, Inc. | 11 | $224 |
| Boehringer Ingelheim | 9 | $148 |
| IBSA Pharma Inc. | 9 | $146 |
| Mannkind Corporation | 7 | $122 |
| Madrigal Pharmaceuticals | 4 | $102 |
| Valeritas, Inc. | 8 | $98 |
| AbbVie | 7 | $89 |
| Radius Health, Inc. | 3 | $82 |
| AstraZeneca | 4 | $81 |
| Amneal Pharmaceuticals LLC | 5 | $75 |
| Ascendis Pharma Endocrinology Inc | 4 | $64 |
| Merck | 4 | $53 |
| Novartis | 2 | $41 |
| Boston Scientific | 1 | $37 |
| Chiesi USA, Inc. | 1 | $35 |
| Lifescan, Inc. | 2 | $31 |
| Dexcom, Inc. | 2 | $29 |
| Johnson & Johnson | 2 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Averitas Pharma Inc. | 1 | $24 |
| Ionis Pharmaceuticals, Inc. | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Antares Pharma, Inc. | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $15 |
| Senseonics, Incorporated | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$250
- Kerendia$125
- FreeStyle Libre 2$109
- FreeStyle Libre$100
How this compares
$7,688 in reported general payments places this provider in the 65th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 276 | $414,035 |
| JardianceEmpagliflozin | 284 | $328,994 |
| MounjaroTirzepatide | 215 | $268,276 |
| TrulicityDulaglutide | 107 | $147,848 |
| Tresiba Flextouch U-100Insulin Degludec | 198 | $135,395 |
| Tresiba Flextouch U-200Insulin Degludec | 97 | $101,078 |
| TradjentaLinagliptin | 76 | $58,554 |
| Humalog Kwikpen U-100Insulin Lispro | 133 | $50,399 |
| RybelsusSemaglutide | 33 | $47,396 |
| Repatha SureclickEvolocumab | 41 | $44,168 |
| Novolog FlexpenInsulin Aspart | 101 | $39,151 |
| JanuviaSitagliptin Phosphate | 43 | $38,287 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $35,545 |
| FarxigaDapagliflozin Propanediol | 35 | $30,919 |
| SynthroidLevothyroxine Sodium | 266 | $26,257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $881 | $487,228369 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $416 | $420,951340 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $148 | $395,011372 claims |
| MerckJanuvia, Janumet Xr | $53 | $47,12057 claims |
| AstraZenecaFarxiga | $81 | $30,91935 claims |
| AbbVieSynthroid | $89 | $26,257266 claims |
| AmgenProlia | $563 | $25,89515 claims |
| BayerKerendia | $349 | $17,67019 claims |
| Sanofi-aventis U.S. LLCLantus | $275 | $5,94013 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $75 | $5,713539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Jacksonville
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Wasim DeebJacksonville$286K
- Khurram WadudJacksonville$77K
- Senan SultanJacksonville$55K
- Firas WardaJacksonville$38K
- Maria Hurtado AndradeJacksonville$36K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.